VRTX — Vertex Pharmaceuticals
Data coverage, completeness and provenance for Vertex Pharmaceuticals in the Stock Market API — Health Care · Biotechnology.
Stored price coverage
Source date: 2026-11-19T21:00:00. Source: yfinance. Collection time is shown separately and does not establish a trade date.
| Date | Close | Currency | Source | Adjustment basis |
|---|---|---|---|---|
| 2026-11-19 | 520.6600 | USD | yfinance | Split- and dividend-adjusted close |
| 2026-11-18 | 536.4500 | USD | yfinance | Split- and dividend-adjusted close |
| 2026-11-17 | 534.2000 | USD | yfinance | Split- and dividend-adjusted close |
| 2026-11-16 | 537.7900 | USD | yfinance | Split- and dividend-adjusted close |
| 2026-11-13 | 538.6000 | USD | yfinance | Split- and dividend-adjusted close |
GET /api/v1/companies/VRTX/prices · Price parameters and adjustment semantics
No archived filings are currently stored for this listing.
Profile
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Employees: 6,400 · Website: https://www.vrtx.com · Profile fields populated: 75%
Data completeness by statement
Share of stored fields populated in the anchor reporting period (FY2025), primary source sec_edgar. Full per-field breakdown: GET /api/v1/companies/VRTX/financials.
Financial statement coverage (USD)
Stored values for the most recent fiscal-year periods, with per-period field counts and the primary source each period came from. Values are shown at reported scale without interpretation.
| Period | Period end | Revenue | Net income | Total assets | Total equity | Fields populated | Source |
|---|---|---|---|---|---|---|---|
| FY2025 (USD) | 2025-12-31 | 29 | sec_edgar | ||||
| FY2024 (USD) | 2024-12-31 | 28 | sec_edgar | ||||
| FY2023 (USD) | 2023-12-31 | 28 | sec_edgar | ||||
| FY2022 (USD) | 2022-12-31 | 28 | sec_edgar | ||||
| FY2021 (USD) | 2021-12-31 | 28 | sec_edgar |
Get VRTX data via the API
The endpoints below describe available datasets for this listing. Missing fields remain unknown. Free API keys — no card required.
Company profile
Name, sector, industry, HQ, employees, market cap, source-tagged.
GET /api/v1/companies/VRTX
Financial statements
Multi-year statements with per-field source tags and completeness.
GET /api/v1/companies/VRTX/financials
Computed ratios
P/E, P/B, ROE, ROA, margins, EPS, debt/equity — formulas documented.
GET /api/v1/companies/VRTX/metrics/summary
News & announcements
Dated press releases and announcements with source links.
GET /api/v1/companies/VRTX/news
Quick start
Create a free key, then:
curl -H "X-API-Key: KEY" https://stockmarketapi.ai/api/v1/companies/VRTX
Query VRTX programmatically
Free tier — instant API key. Built for AI agents.
Other NASDAQ · Health Care companies covered
Frequently Asked Questions
- What data does the API provide for VRTX?
- Stored coverage for VRTX: price data available, financial statements available, 0 archived filings. REST endpoints are under /api/v1/companies/VRTX; inspect available source metadata for provenance.
- How complete is VRTX's financial data?
- The anchor reporting period (FY2025) has 94.1% of the 17 core statement fields populated. Primary source: sec_edgar.
- What reporting periods are covered for VRTX?
- 5 fiscal-year periods are stored (FY2021–FY2025), with per-period field counts and source tags available via /api/v1/companies/VRTX/financials.
- Where does VRTX's data come from?
- Stored price source: yfinance. Primary source for the statement snapshot: sec_edgar. Inspect available period and field source tags at /api/v1/companies/VRTX/financials; missing tags do not establish provenance.